[stock_market_widget type=”card” template=”basic2″ assets=”NVO” realtime=”true” api=”yahoo-finance”]
Most people who take one of today’s popular weight-loss drugs do so with a weekly injection, a small ritual they repeat for as long as they stay on the medicine. A California company thinks there is a better way, and this week it drew attention from the largest name in the field.
Vivani Medical, Inc. (NASDAQ: VANI) reported that it had signed an agreement allowing Novo Nordisk A/S (NYSE: NVO, CPH: NOVO-B.CO) to evaluate one of its experimental products. The product, known as NPM-139, is a miniature implant designed to release semaglutide, the same active ingredient found in the widely used treatments Ozempic and Wegovy, slowly and steadily beneath the skin.
Some background helps here. Semaglutide belongs to a class of medicines called GLP-1 drugs, which help people manage their weight by curbing appetite and slowing digestion. These treatments have become some of the most talked about products in medicine, but they usually require regular injections, and many patients stop taking them over time.
Vivani’s idea is to place the drug inside a small implant, roughly the size of a matchstick, that a doctor inserts under the skin and that keeps working for months at a time. The company calls the underlying technology its NanoPortal platform, and it is building the weight-management implant to last as long as six months, with the longer-term goal of a version that could work for a full year. The appeal, in the company’s telling, is convenience and steadiness, since a patient would not have to remember a weekly shot, and the implant could be removed if treatment ever needed to stop.
The agreement with Novo Nordisk is narrow, and Vivani was careful to say so. Novo Nordisk will run its own internal evaluation of the semaglutide implants that Vivani prepares, and nothing in the arrangement gives the Danish company exclusive rights to the implant or to the NanoPortal technology behind it. In plain terms, this is a look, not a partnership. There is no licensing deal, no upfront payment disclosed, and no promise that anything further will follow.
Even so, the interest carries weight. Novo Nordisk helped build the modern market for these drugs, and its willingness to study a tiny competitor’s approach is the kind of signal that outside observers tend to notice. For a company of Vivani’s size, that recognition is arguably the real headline. As of its most recent close, Vivani carried a market value of roughly $110 million, which puts it firmly in the micro-cap corner of the market, far below the household names in the weight-loss business.
Separately from the Novo Nordisk agreement, Vivani has said it expects to begin its first human study of NPM-139 in the middle of 2026. That trial is designed to test the implant against Wegovy injections, giving the company an early read on how its slow-release approach compares with the injectable version patients already use. First-in-human studies are early steps, and they measure safety and basic performance rather than final proof that a product works, so the results, whenever they arrive, will be a beginning rather than a conclusion.
What all of this adds up to is a small but real moment for a small developer. A company worth a little over $110 million has persuaded the biggest player in its field to take a closer look at its lead product, and it is about to put that product in front of human volunteers for the first time. Whether the implant lives up to its promise, and whether Novo Nordisk’s curiosity ever becomes something more concrete, will take years and more data to answer. For now, Vivani has earned a moment of attention, and in a field this crowded, attention is worth something.
